A Phase II Study of IL-18 in Melanoma Patients
Phase of Trial: Phase II
Latest Information Update: 31 Jul 2017
At a glance
- Drugs Iboctadekin (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 15 Feb 2009 Primary endpoint 'Objective clinical response rate' has not been met.
- 09 Oct 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 02 Sep 2005 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History